Breaking News Instant updates and real-time market news.

CATB

Catabasis Pharmaceuticals

$7.67

0.17 (2.27%)

08:10
06/27/19
06/27
08:10
06/27/19
08:10

Catabasis Pharmaceuticals provides update on edasalonexent, qualitative research

Catabasis Pharmaceuticals shared an update on the clinical development of edasalonexent, a novel NF-kB inhibitor for the treatment of Duchenne muscular dystrophy, or DMD, this week at the Parent Project Muscular Dystrophy, or PPMD conference. Catabasis shared progress in the edasalonexent Phase 3 PolarisDMD trial. Screening is ongoing for the randomized, double-blind, placebo-controlled trial in the United States, Canada, Australia, the United Kingdom, Ireland, Sweden, Germany and Israel and making progress. Clinical trial sites globally are enrolling and sites in the United Kingdom, Ireland, Sweden, Germany and Israel are at capacity and no longer accepting additional patients. The trial is active in all planned countries with 37 sites open for enrollment. Top-line results from the study are expected in the second half of 2020 and are anticipated to support an NDA filing in early 2021. Catabasis also shared insights from a recent blinded qualitative research project that collected information from in-depth interviews with approximately 30 physicians treating boys affected by DMD, caregivers and patient advocacy representatives in the United States that was sponsored by Catabasis. A key observation from the research was that members of the DMD community prioritized treatments that will go beyond skeletal muscle and positively impact additional important aspects of DMD, including cardiac and pulmonary effects. Participants also shared their hope that treatments will provide durable benefits and improve quality of life. Additionally, physicians predicted that the majority of boys will receive combination therapy for the treatment of DMD within the next few years. Data from the edasalonexent MoveDMD Phase 2 open-label extension study were also presented at the PPMD conference. Through 72 weeks of treatment compared to an off-treatment control period, patients treated with edasalonexent demonstrated preserved muscle function and substantially slowed DMD disease progression across all four assessments of muscle function. Preclinical data and clinical biomarker data from the MoveDMD trial suggest that edasalonexent could have potential benefits in skeletal muscle, diaphragm and heart. Edasalonexent has been well tolerated through more than 55 patient-years of treatment. In the Phase 3 PolarisDMD trial, Catabasis plans to enroll approximately 125 patients ages 4 to 7 regardless of mutation type who have not been on steroids for at least 6 months. Boys on a stable dose of eteplirsen may be eligible to enroll. Boys from the MoveDMD open-label extension and their eligible siblings can now enroll in the GalaxyDMD open-label extension trial. Boys who complete the Phase 3 PolarisDMD trial as well as their eligible siblings will also have the opportunity to participate in the GalaxyDMD open-label extension trial. Boys can begin or continue treatment with an approved exon skipping therapy in the GalaxyDMD trial. The GalaxyDMD trial has a streamlined schedule with visits to trial sites every six months and is designed to collect long-term safety data to support registration filings. The trial is also monitoring assessment of muscle function and bone health.

CATB Catabasis Pharmaceuticals
$7.67

0.17 (2.27%)

08/10/18
SBSH
08/10/18
NO CHANGE
Target $1.5
SBSH
Buy
Catabasis price target lowered to $1.50 from $2.50 at Citi
Citi analyst Joel Beatty lowered his price target for Catabasis Pharmaceuticals to $1.50 to reflect the recent share offering. The analyst, however, keeps a Buy rating on the shares. He believes the favorable trends in the Phase 2 Duchenne muscular dystrophy data for lead agent Edasalonexent provide enough support that the Phase 3 trial may be a success. As such, he thinks Catabasis should be trading above the current cash value.
01/14/19
OPCO
01/14/19
NO CHANGE
Target $77
OPCO
Outperform
Catabasis Pharmaceuticals price target raised to $77 from $7 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Catabasis Pharmaceuticals to $77 from $7 after the company announced a 10-for-1 reverse stock split and given his upgraded conviction on the probability of the PolarisDMD phase 3 trial for edasanolexent being positive. The analyst reiterates an Outperform rating on the shares.
01/31/19
WEDB
01/31/19
NO CHANGE
Target $28
WEDB
Outperform
Catabasis Pharmaceuticals price target raised to $28 from $3 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Catabasis Pharmaceuticals to $28 from $3 to take into account the 10-for-1 reverse stock split that Catabasis previously executed. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

CSX

CSX

$79.47

0.95 (1.21%)

15:04
07/16/19
07/16
15:04
07/16/19
15:04
Options
CSX options imply 5.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

15:00
07/16/19
07/16
15:00
07/16/19
15:00
General news
Fed's Evans said a little more accommodation would be helpful »

Fed's Evans said a…

ESV

Ensco Rowan

$8.24

-0.21 (-2.49%)

14:55
07/16/19
07/16
14:55
07/16/19
14:55
Options
Ensco put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 27

    Aug

FB

Facebook

$203.23

-0.7 (-0.34%)

14:49
07/16/19
07/16
14:49
07/16/19
14:49
Hot Stocks
Facebook's Perault says Instagram, WhatsApp takeovers have benefited users »

In prepared remarks ahead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

  • 24

    Jul

UAL

United Continental

$94.14

2.84 (3.11%)

14:49
07/16/19
07/16
14:49
07/16/19
14:49
Options
United Continental options imply 6.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

MNST

Monster Beverage

$65.31

0.03 (0.05%)

, PM

Philip Morris

$81.31

-0.13 (-0.16%)

14:44
07/16/19
07/16
14:44
07/16/19
14:44
Recommendations
Monster Beverage, Philip Morris, British American Tobacco, Altria Group, Nielsen analyst commentary at Wells Fargo »

Wells says Nielsen…

MNST

Monster Beverage

$65.31

0.03 (0.05%)

PM

Philip Morris

$81.31

-0.13 (-0.16%)

BTI

British American Tobacco

$36.42

-0.23 (-0.63%)

MO

Altria Group

$49.20

-0.36 (-0.73%)

NLSN

Nielsen

$23.36

-0.05 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 30

    Jul

CHFC

Chemical Financial

$40.69

-0.11 (-0.27%)

, TCF

TCF Financial

$20.63

-0.03 (-0.15%)

14:38
07/16/19
07/16
14:38
07/16/19
14:38
Hot Stocks
Federal Reserve approves Chemical Financial deal to acquire TCF Financial »

The Federal Reserve Board…

CHFC

Chemical Financial

$40.69

-0.11 (-0.27%)

TCF

TCF Financial

$20.63

-0.03 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 25

    Jul

  • 23

    Sep

14:32
07/16/19
07/16
14:32
07/16/19
14:32
Conference/Events
Morgan Stanley India phama analyst to hold an analyst/industry conference call »

India Pharmaceuticals…

F

Ford

$10.43

0.015 (0.14%)

, GM

General Motors

$39.21

-0.15 (-0.38%)

14:25
07/16/19
07/16
14:25
07/16/19
14:25
Periodicals
U.S. car makers open UAW contract talks as labor costs rise, WSJ reports »

Major U.S. car makers are…

F

Ford

$10.43

0.015 (0.14%)

GM

General Motors

$39.21

-0.15 (-0.38%)

FCAU

Fiat Chrysler

$13.61

-0.565 (-3.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 12

    Aug

  • 23

    Oct

JBLU

JetBlue

$19.53

0.8 (4.27%)

14:25
07/16/19
07/16
14:25
07/16/19
14:25
Options
JetBlue call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

GOOG

Alphabet

$1,152.76

2.37 (0.21%)

14:25
07/16/19
07/16
14:25
07/16/19
14:25
Conference/Events
Senate Judiciary Committee to hold a hearing »

The Subcommittee on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 25

    Jul

  • 08

    Aug

  • 27

    Oct

14:25
07/16/19
07/16
14:25
07/16/19
14:25
Conference/Events
JPMorgan SMid Cap biotech analyst to hold an analyst/industry conference call »

SMid Biotech Analyst Fye,…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
07/16/19
07/16
14:17
07/16/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
07/16/19
07/16
14:16
07/16/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFRX

ContraFect

$0.47

-0.0187 (-3.83%)

14:12
07/16/19
07/16
14:12
07/16/19
14:12
Conference/Events
ContraFect management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

14:10
07/16/19
07/16
14:10
07/16/19
14:10
General news
More from Kaplan: he thinks the funds rate will stabilize after just one rate cut »

More from Kaplan: he…

ATEC

Alphatec

$4.38

-0.06 (-1.35%)

14:09
07/16/19
07/16
14:09
07/16/19
14:09
Syndicate
Breaking Syndicate news story on Alphatec »

Alphatec files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 12

    Sep

SPOT

Spotify

$154.15

-0.13 (-0.08%)

, AAPL

Apple

$203.82

-1.36 (-0.66%)

14:08
07/16/19
07/16
14:08
07/16/19
14:08
Hot Stocks
Spotify slides after Apple said to plan original, exclusive podcasts »

Spotify (SPOT) shares are…

SPOT

Spotify

$154.15

-0.13 (-0.08%)

AAPL

Apple

$203.82

-1.36 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 31

    Jul

MCD

McDonald's

$213.70

-0.48 (-0.22%)

, UBER

Uber

$44.37

-0.14 (-0.31%)

14:04
07/16/19
07/16
14:04
07/16/19
14:04
Hot Stocks
McDonald's adds DoorDash as U.S. delivery partner »

McDonald's USA and…

MCD

McDonald's

$213.70

-0.48 (-0.22%)

UBER

Uber

$44.37

-0.14 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 08

    Aug

APRN

Blue Apron

$12.46

4.81 (62.88%)

14:00
07/16/19
07/16
14:00
07/16/19
14:00
Options
Explosive action in BlueApron as partnership with BYND anhiliates shorts »

Explosive action in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

AAPL

Apple

$204.13

-1.05 (-0.51%)

, SPOT

Spotify

$154.63

0.35 (0.23%)

13:59
07/16/19
07/16
13:59
07/16/19
13:59
Periodicals
Apple to fund original podcasts in challenge to Spotify, Bloomberg says »

Apple (AAPL) plans to…

AAPL

Apple

$204.13

-1.05 (-0.51%)

SPOT

Spotify

$154.63

0.35 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 31

    Jul

TSLA

Tesla

$252.11

-1.3 (-0.51%)

13:55
07/16/19
07/16
13:55
07/16/19
13:55
Hot Stocks
Tesla CEO Musk says cost of FSD option will increase 'every few months' »

Tesla CEO Elon Musk said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 06

    Aug

CARS

Cars.com

$20.95

-0.56 (-2.60%)

13:55
07/16/19
07/16
13:55
07/16/19
13:55
Options
Cars.com put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$28.93

-0.29 (-0.99%)

, ABT

Abbott

$83.27

-0.53 (-0.63%)

13:50
07/16/19
07/16
13:50
07/16/19
13:50
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$28.93

-0.29 (-0.99%)

ABT

Abbott

$83.27

-0.53 (-0.63%)

USB

U.S. Bancorp

$53.04

-0.07 (-0.13%)

PNC

PNC Financial

$138.85

-1.33 (-0.95%)

PGR

Progressive

$84.25

0.245 (0.29%)

BK

BNY Mellon

$43.20

0.05 (0.12%)

OMC

Omnicom

$84.47

0.46 (0.55%)

TXT

Textron

$54.17

0.74 (1.39%)

CMA

Comerica

$71.70

0.34 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 26

    Aug

  • 06

    Sep

  • 16

    Oct

CSX

CSX

$79.79

1.27 (1.62%)

, CTAS

Cintas

$243.78

0.47 (0.19%)

13:49
07/16/19
07/16
13:49
07/16/19
13:49
Earnings
Notable companies reporting after market close »

Notable companies…

CSX

CSX

$79.79

1.27 (1.62%)

CTAS

Cintas

$243.78

0.47 (0.19%)

UAL

United Continental

$94.36

3.06 (3.35%)

FNF

Fidelity National

$41.43

-0.12 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

  • 01

    Aug

  • 26

    Aug

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.